Mimosine, or b -[N-(3-hydroxy-4-oxypyridyl)]-a-aminopropionic acid, is a non-proteinogenic amino acid found in the members of Mimosoideae clade. It has been found to be a reversible inhibitor of DNA replication because of its ability to strongly bind to metals in the active site of many enzymes. Based on this activity, mimosine has been reported to have antimicrobial, antifungal and antiviral properties. Moreover, it has also found its way on therapeutic applications, showing anticancer activity and anti-inflammatory properties. One of us recently proposed mimosine containing peptides as decorporation agents of Al(III), a recognized neurotoxin. This proposal is based on the structural similarity of mimosine to deferiprone (DFP), a drug used for Fe(II) removal that has also shown promising results on treating the accumulation of high-valent metal cations, such as Al(III) and Fe(III). The proposed compounds had similar structures to that of deferoxamine (DFO), another drug used for Fe(II) decorporation (see Figure ). DFO is able to bind to all six vacancies of the Fe(II) making it a very strong ligand. Studies have shown that DFO is a more effective decorporation agent than DFP. However, it suffers from other issues, such as being poorly absorbed and some secondary effects. Thus, the development of novel polypeptides able to strongly bind to all six vacancies of Al(III) can be a highly promising approach to creating decorporation agent candidates. However, the effects of this non-protein amino-acid in the context of a polypeptide chain have not been explored.